Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.

Rheumatology (Oxford) 2018 04;57(4):677-687

Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

Objectives: To describe glucocorticoid (GC) use in the SLICC inception cohort and to explore factors associated with GC use. In particular we aimed to assess temporal trends in GC use and to what extent physician-related factors may influence use.

Methods: Patients were recruited within 15 months of diagnosis of SLE from 33 centres between 1999 and 2011 and continue to be reviewed annually. Descriptive statistics were used to detail oral and parenteral GC use. Cross sectional and longitudinal analyses were performed to explore factors associated with GC use at enrolment and over time.

Results: We studied 1700 patients with a mean (s.d.) follow-up duration of 7.26 (3.82) years. Over the entire study period, 1365 (81.3%) patients received oral GCs and 447 (26.3%) received parenteral GCs at some point. GC use was strongly associated with treatment centre, age, race/ethnicity, sex, disease duration and disease activity. There was no change in the proportion of patients on GCs or the average doses of GC used over time according to year of diagnosis.

Conclusion: GCs remain a cornerstone in SLE management and there have been no significant changes in their use over the past 10-15 years. While patient and disease factors contribute to the variation in GC use, between-centre differences suggest that physician-related factors also contribute. Evidence-based treatment algorithms are needed to inform a more standardized approach to GC use in SLE.

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kex444DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888922PMC
April 2018
37 Reads

Publication Analysis

Top Keywords

factors associated
12
explore factors
8
factors contribute
8
inception cohort
8
physician-related factors
8
factors
5
gcs 447
4
oral gcs
4
gcs
4
813% patients
4
received oral
4
patients received
4
263% received
4
associated treatment
4
treatment centre
4
centre age
4
point associated
4
gcs point
4
1365 813%
4
received parenteral
4

References

(Supplied by CrossRef)
A double-blind controlled trial of methylprednisolone infusions in systemic lupus-erythematosus using individualized outcome assessment
Edwards et al.
Ann Rheum Dis 1987
Flares in lupus: Outcome assessment trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone
Danowski et al.
J Rheumatol 2006
Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis
Zeher et al.
Lupus 2011
Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications
Badsha et al.
Lupus 2002
Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares
Kong et al.
Lupus 2004
Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis
Ruiz-Arruza et al.
Autoimmun Rev 2015
Prednisone in lupus nephritis: How much is enough?
Ruiz-Irastorza et al.
Autoimmun Rev 2014
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
Condon et al.
Ann Rheum Dis 2013
Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study
Fischer-Betz et al.
J Rheumatol 2012
Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines
Arthritis Rheum 1999
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
Bertsias et al.
Ann Rheum Dis 2008

Similar Publications